Congress-IPS
Congress-IPS-Mobile

Acute Hepatic Porphyria (AHP)

International Porphyrias Symposium (IPS) 2025

Congress Details

calanderOctober 9-12, 2025

locationWashington, D.C.

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Image
agenda icon

Congress Materials

Image
icon Presentation Type
Poster
Image
location icon Location
Washington, D.C.
Image
icon Title
Chronic symptoms reported by patients with acute hepatic porphyria in the POWER study in a subgroup analysis of nonrecurrent patients
Image
icon Presentation Type
Poster
Image
location icon Location
Washington, D.C.
Image
icon Title
Annualized attack rate reductions vs historical data and hemin use of patients with acute hepatic porphyria in phase 3 ENVISION trial who were not attack-free after 6 months of givosiran treatment
Image
icon Presentation Type
Poster
Image
location icon Location
Washington, D.C.
Image
icon Title
ENVISION study EQ-5D analysis to assess relationship between annualized attack rate with expanded criteria and chronic symptoms in patients with acute hepatic porphyria
Image
icon Presentation Type
Poster
Image
location icon Location
Washington, D.C.
Image
icon Title
The symptom and quality-of-life burden of Acute Hepatic Porphyria (AHP): Evidence from a systematic literature review